ArticleFrontiers in endocrinology2025
Exploring the mechanism of Zishen Quyu Jiedu formula in treating endometriosis based on network pharmacology and experimental verification.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Zishen Quyu Jiedu formula (ZQYJDF) is a commonly used prescription for endometriosis (EMs) with clinical efficacy. However, its active components and potential mechanisms remain unknown. This study aimed to identify the key targets and signaling pathways involved in the treatment of EMs by ZSQYJDF and to clarify its mechanism. Materials and methods: Multiple databases were integrated to screen the effective components of ZSQYJDF and their protein targets, with redundancies removed. EMs-related genes were obtained from several disease databases. A drug-component-target network was constructed using overlapping targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to identify key pathways and proteins. An autologous transplantation rat model of EMs was established. Hematoxylin and eosin (H&E) staining was used to observe lesion morphology; immunohistochemistry (IHC) was used to assess positive expression of NRF2, HO1, and NQO1; serum SOD, MDA, GSHPx, 8epiPGF2α, IL6, IL1β, and TNFα were measured by ELISA; and mRNA and protein levels of NRF2, HO1, NQO1, and KEAP1 in endometrial tissue were detected by qPCR and Western blot. Results: comparisonon of the screened compounds with 1,225 known disease-related targets identified 134 potential targets for ZSQYJDF. GO terms were enriched in response to oxidative stress and cellular responses to oxidative stress. KEGG pathways were enriched in the TNF, NRF2, and HIF signaling pathways. HPLC-QOrbitrap-MS identified and inferred 48 compounds. In Conclusion: Utilizing methods including network pharmacology, HPLC-Q-Orbitrap-MS component identification, and animal experiments, the main active components and potential therapeutic targets of ZSQYJDF were identified, and its mechanism of action in treating EMs was preliminarily elucidated, providing a scientific basis for further research on EMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.